awmsg logo



icatibant acetate (Firazyr®)


Reference No. 3293

Publication date:
12/06/2018


Appraisal information

icatibant acetate (Firazyr®) 30 mg solution for injection


Company: Shire Orphan Therapies GmbH
BNF category: Respiratory system
NMG meeting date: 11/04/2018
AWMSG meeting date: 23/05/2018
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 0818
Ratification by Welsh Government: 11/06/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Icatibant acetate (Firazyr) is recommended as an option for use within NHS Wales for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older, with C1 esterase-inhibitor deficiency. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download